• Jobs
  • Startups
  • Hire
LoginSign up

Isomorphic Labs

Isomorphic Labs has 11 open roles, 1 posted in the last 30 days. Funding stage: Series B. Last round: $2.1B, May 12, 2026.

Open roles

  • Isomorphic Labs logo
    Senior Legal Counsel, Corporate Transactions, Cambridge, MA

    Isomorphic Labs

    • Cambridge, MA
    • Hybrid · Senior
    AI-native
    Greenhouse
    Posted 14d ago
  • Isomorphic Labs logo
    Technical Program Manager (Drug Discovery), Cambridge, MA

    Isomorphic Labs

    • Cambridge, MA
    • Hybrid
    Greenhouse
    Posted 35d ago
  • Isomorphic Labs logo
    Senior Finance Business Partner (Clinical), Cambridge, MA

    Isomorphic Labs

    • Cambridge, MA
    • Hybrid · Senior
    AI-native
    Greenhouse
    Posted 37d ago
  • Isomorphic Labs logo
    Associate Director, Clinical Supply Chain, Cambridge, MA

    Isomorphic Labs

    • Cambridge, MA
    • Hybrid · Director / Executive
    Greenhouse
    Posted 46d ago
  • Isomorphic Labs logo
    Senior Legal Counsel, Clinical

    Isomorphic Labs

    • Cambridge, MA
    • Hybrid · Senior
    AI-native
    Greenhouse
    Posted 50d ago
  • Isomorphic Labs logo
    Research Leader (Toxicology), Cambridge, MA

    Isomorphic Labs

    • Cambridge, MA
    • Hybrid · Senior
    AI-native
    Greenhouse
    Posted 63d ago
Show all roles

About

Isomorphic Labs logo

Isomorphic Labs

We are reimagining the entire drug discovery process from first principles with an AI-first approach.

Isomorphic Labs is an AI-first drug design and development company that transforms drug discovery by using machine learning to design and evaluate new medicines. It builds on research from DeepMind, including the AlphaFold system, which is used to predict protein structures and understand how biological molecules interact. The company develops AI models that simulate biological processes and support the design of drug candidates across multiple disease areas. Its platform integrates predictive and generative AI systems to explore chemical space, identify therapeutic targets, and propose new molecular structures with potential medical applications. It collaborates with pharmaceutical companies on research programs in areas such as oncology and immunology, with the aim of accelerating early-stage drug discovery and improving candidate selection. The organization also develops internal pipelines of AI-designed drug candidates and is progressing toward clinical testing of its first progr

Private companySeries BMega roundIn the newsAI-product
Unlock human wisdom
ThesisTermsPrivacy
Founded
2021
HQLondon, United Kingdom
Size201–500 employees
IndustryBiotechnology Research
Funding
  • Series B · $2.1B · May 12, 2026
Investors
Thrive Capital
News
  • Isomorphic Labs' Max Jaderberg: Rat Tests Are Only 30% Predictive of Human Toxicity — and That's the Case for AI Drug Discovery
  • Isomorphic Labs CEO Max Jaderberg says drug discovery needs six more AlphaFold-sized breakthroughs, not one
  • Isomorphic Labs president says all drugs will be AI-designed as first trials near a year-end target
  • Isomorphic Labs in talks to raise $5bn at a $50bn valuation, Bloomberg reports
  • Isomorphic Labs in Talks for 5 Billion Dollars at 50 Billion Dollar Valuation, Bloomberg Reports

Claim isomorphiclabs.com

Work at isomorphiclabs.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.